Author:
Ilyas Shazia,Tabasum Raheela,Iftikhar Ali,Nazir Mamoona,Hussain Amina,Hussain Aroosha,Ali Muhammad Sajjad,Saleem Farooq,Saleem Uzma,Froeyen Matheus,Abdullah Iskandar,Mirza Muhammad Usman,Ahmad Sarfraz
Abstract
AbstractIfosfamide is a widely used chemotherapeutic agent having broad-spectrum efficacy against several tumors. However, nephro, hepato, neuro cardio, and hematological toxicities associated with ifosfamide render its use limited. These side effects could range from organ failure to life-threatening situations. The present study aimed to evaluate the attenuating efficiency of Berberis vulgaris root extract (BvRE), a potent nephroprotective, hepatoprotective, and lipid-lowering agent, against ifosfamide-induced toxicities. The study design comprised eight groups of Swiss albino rats to assess different dose regimes of BvRE and ifosfamide. Biochemical analysis of serum (serum albumin, blood urea nitrogen, creatinine, alanine transaminase, aspartate transaminase, alkaline phosphatase, lactate dehydrogenase, total cholesterol, and triglycerides) along with complete blood count was performed. Kidney, liver, brain, and heart tissue homogenates were used to find malondialdehyde, catalase, and glutathione S-transferase levels in addition to the acetylcholinesterase of brain tissue. The results were further validated with the help of the histopathology of the selected organs. HeLa cells were used to assess the effect of BvRE on ifosfamide cytotoxicity in MTT assay. The results revealed that pre- and post-treatment regimens of BvRE, as well as the combination therapy exhibited marked protective effects against ifosfamide-induced nephro, hepato, neuro, and cardiotoxicity. Moreover, ifosfamide depicted a synergistic in vitro cytotoxic effect on HeLa cells in the presence of BvRE. These results corroborate that the combination therapy of ifosfamide with BvRE in cancer treatment can potentiate the anticancer effects of ifosfamide along with the amelioration of its conspicuous side effects.
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Organisation, W. H. (2020). https://www.who.int/cancer/resources/keyfacts/en/ (accessed on 24 March 2020).
2. Schirrmacher, V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (review). Int. J. Oncol. 54, 407–419. https://doi.org/10.3892/ijo.2018.4661 (2019).
3. Rang, H., Dale, M. & Ritter, J. Anticancer Drugs, Textbook of Pharmacology (Elsevier, Amsterdam, 2012).
4. Takimoto, C. H. & Calvo, E. Principles of Oncologic Pharmacotherapy: In Cancer Management, a Multidisciplinary Approach (PRR, Melville, New York, 2008).
5. Zhang, J., Tian, Q. & Zhou, S.-F. Clinical pharmacology of cyclophosphamide and ifosfamide. Curr. Drug Ther. 1, 55–84 (2006).
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献